TBC....................................................................
We want to solve immune dysfunction.
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or
target cells correctly. We're progressing first-in-class antigen modulators through the clinic,
developed to treat disease by controlling T cell activation. Our technology modulates antigen
presentation, flicking a switch inside cells to alter their appearance to the immune system.
This approach marks a fundamental shift in how we treat people living with autoimmune disorders,
cancers and infectious diseases.
This is a unique opportunity to play a key role during one of the most important phases of the
company's development. You will shape the financial strategy of the organisation, support a planned
IPO, and help build the finance infrastructure required for long-term success as a listed
biotechnology company.
Open Post · Greywolf Therapeutics